Application 761195

Type
BLA
Sponsor
ARGENX BV

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761195Vyvgartefgartigimod alfa-fcab351(a)Rx2026-09-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001VYVGARTEFGARTIGIMOD ALFAINJECTABLE;INJECTION400MGNoNo

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
VYVGARTEFGARTIGIMOD ALFAargenx US8aefc8e3-26d6-4ff6-aab9-a7542927e0842026-05-13Warnings, Adverse reactionsExact identifier
application number: BLA761195
ndc (product): 73475-3041

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 3 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
73475-3041VYVGARTEFGARTIGIMOD ALFAargenx USBLACurrent
73475-3041VYVGARTEFGARTIGIMOD ALFAargenx USBLACurrent
73475-3041VYVGARTEFGARTIGIMOD ALFAargenx USBLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
85944SUPPL 2026-05-18
85874SUPPL 2026-05-11
83861SUPPL 2025-10-21
83826SUPPL 2025-10-20
79364SUPPL 2024-08-12
79358SUPPL 2024-08-09
79227SUPPL 2024-07-29
79206SUPPL 2024-07-25
76785SUPPL 2023-12-13
76779SUPPL 2023-12-13
69909ORIG2022-01-19
69723ORIG2021-12-21
69636ORIG2021-12-19